BSE filing, NSE: ZENSARTECH. Summary written from the filing by ALFA Finder's alert engine.
Zensar Technologies Ltd: key numbers
- Share price
- ₹497.00
- Market cap
- ₹11,311 Cr
- Revenue (annual)
- ₹5,687 Cr
- Net profit (annual)
- ₹774.6 Cr
- P/E (TTM)
- 14.6×Sector 23.0×
- Promoter holding
- 48.98%-0.01% QoQ
- FII holding
- 10.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zensar Technologies Ltd
All →Zensar Technologies Other Announcement
Zensar Technologies submitted its Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming RTA dematerialization records were furnished to depositories.
Zensar Technologies Employee Stock Options
Zensar Technologies allotted 162,619 equity shares upon the exercise of ESOPs by employees. This allotment increases the company's issued and subscribed share capital.
Zensar Technologies Board Meeting Date
Zensar Technologies has scheduled a board meeting for October 28, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Zensar Technologies Credit Rating
ICRA Limited has reaffirmed the credit rating of Zensar Technologies for its long-term and short-term fund/non-fund based bank facilities, totaling ₹191 Crore.
- Value
- ₹191.0 Cr
Zensar Technologies Employee Stock Options
Designated person Vijayasimha Alilughatta acquired 8,983 shares of Zensar Technologies through an ESOP exercise. The transaction is valued at ₹0.43 Crore.
- Value
- ₹0.43 Cr
Zensar Technologies Employee Stock Options
Zensar Technologies has allotted 25,691 equity shares to employees following the exercise of their vested ESOPs.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.